F

    Forte Biosciences Inc (FBRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $76.99
    +0.00 (+0.00%)

    Market Cap: $1.63B

    Last updated: Aug 27, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(21/38)
    Avg Surprise
    -70.34%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.78
    Range$-0.78 - $-0.78
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-1.00-28.7%
    60d ago$-1.00-28.7%
    30d ago$-1.00-28.7%
    7d ago$-0.93-19.4%
    Current$-0.78
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.11
    Range$-1.66 - $-0.40
    5 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.11---
    Sep 26EST
    		-$-0.78---
    Jun 26
    Reported Aug 11
    		$-0.97$-1.08+10.19%Beat-1.0%
    Mar 26
    Reported May 11
    		$-1.24$-1.16-6.90%Miss+9.5%
    Dec 25
    Reported Mar 31
    		$-1.45$-1.15-26.36%Miss-23.9%
    Sep 25
    Reported Nov 14
    		$-0.99$-1.07+7.48%Beat+78.2%
    Jun 25
    Reported Aug 14
    		$-0.96$-1.11+13.51%Beat+85.8%
    Mar 25
    Reported May 15
    		$-1.37$-0.89-53.93%Miss+65.8%
    Dec 24
    Reported Mar 24
    		$-1.17$-0.14-735.71%Miss-515.8%
    Sep 24
    Reported Nov 14
    		$-4.54$-7.12+36.24%Beat-1646.2%
    Jun 24
    Reported Aug 14
    		$-6.75$-4.12-63.84%Miss-1507.1%
    Mar 24
    Reported May 13
    		$-4.00$-4.25+5.88%Beat-1622.7%
    Dec 23
    Reported Mar 18
    		$-0.19$-0.28+32.14%Beat+17.4%
    Sep 23
    Reported Nov 13
    		$-0.26N/A+54.39%Beat+94.2%
    Jun 23
    Reported Aug 14
    		$-0.42$-0.42+0.00%Beat+92.0%
    Mar 23
    Reported May 15
    		$-0.23$-0.32+27.44%Beat-36.6%
    Dec 22
    Reported Mar 31
    		$-0.23$-0.16-43.75%Miss-9.5%
    Sep 22
    Reported Nov 14
    		$-4.50$-3.75-20.00%Miss+66.7%
    Jun 22
    Reported Aug 15
    		$-5.25$-4.75-10.53%Miss+51.2%
    Mar 22
    Reported May 16
    		$-0.17$-0.17+0.00%Beat+98.1%
    Dec 21
    Reported Mar 31
    		$-0.21$-0.32+34.38%Beat+43.2%
    Sep 21
    Reported Nov 8
    		$-13.50$-9.31-45.01%Miss-20.0%
    Jun 21
    Reported Aug 16
    		$-10.75$-10.92+1.56%Beat+42.0%
    Mar 21
    Reported May 10
    		$-9.00$-12.28+26.71%Beat-39.5%
    Dec 20
    Reported Mar 16
    		$-0.37$-0.57+35.09%Beat+95.1%
    Sep 20
    Reported Nov 9
    		$-11.25$-7.62-47.64%Miss+3.8%
    Jun 20
    Reported Aug 10
    		$-18.52$-4.50-311.56%Miss-71.5%
    Mar 20
    Reported Apr 23
    		$-6.45$-6.60+2.27%Beat+41.9%
    Dec 19
    Reported Feb 27
    		$-7.50$-8.55+12.28%Beat+47.9%
    Sep 19
    Reported Nov 12
    		$-11.70$-10.49-11.53%Miss-3800.0%
    Jun 19
    Reported Aug 8
    		$-10.80$-11.34+4.76%Beat+11.1%
    Mar 19
    Reported May 7
    		$-11.10$-15.15+26.73%Beat-13.8%
    Dec 18
    Reported Feb 27
    		$-14.40$-10.26-40.35%Miss-74.5%
    Sep 18
    Reported Nov 8
    		$-0.30N/A+95.56%Beat+96.0%
    Jun 18
    Reported Aug 7
    		$-12.15$-8.90-36.52%Miss-44.6%
    Mar 18
    Reported May 10
    		$-9.75$-0.57-1610.53%Miss+84.2%
    Dec 17
    Reported Mar 8
    		$-8.25$-9.37+11.95%Beat-
    Sep 17
    Reported Nov 8
    		$-7.50$-8.62+12.99%Beat-
    Jun 17
    Reported Aug 9
    		$-8.40$-7.80-7.69%Miss-
    Mar 17
    Reported Apr 13
    		$-61.65$-40.42-52.52%Miss-

    Key Metrics

    Valuation
    P/E Ratio-16.56EV/EBITDA1.87x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-62.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio10.01xQuick Ratio10.01x
    Trading Statistics
    Beta2.65Avg Volume1.84M
    52-Week High$77.2052-Week Low$10.11

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$76.92
    SMA 20$76.83
    SMA 50$53.93
    SMA 200$32.54
    EMA 10$76.70
    EMA 20$73.62
    EMA 50$59.59
    EMA 200$35.81

    MACD

    Line: 5.67Signal: 7.38Hist: -1.71

    ADX

    ADX: 84.8+DI: 48.5-DI: 2.6

    Aroon & PSAR

    Aroon Up20.0
    Aroon DownN/A
    PSAR$77.19

    Bollinger Bands

    Upper Band$77.09
    Lower Band$76.56
    %B Position69%(Middle)
    Band Width0.81

    RSI (14-Day)

    Overbought
    84.4

    Momentum Oscillators

    Stoch %K95.9
    Stoch %D96.6
    Williams %R-4.2
    ROC (10d)0.2%
    Momentum0.13
    CCI (20d)116.1
    MFI (14d)77.0

    Volatility Measures

    ATR (14d)$1.16(1.5%)
    StdDev (20d)0.13
    Hist Vol2.3%(Low)

    Volume Flow

    VWAP$76.99
    OBV42.2M
    AD Line9.9M
    CMF (20d)0.051

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol RatioN/A
    VWMA (20d)$76.85

    Pivot Points

    R3$77.05
    R2$77.02
    R1$77.01
    Pivot Point$76.98
    S1$76.97
    S2$76.94
    S3$76.93

    Advanced Oscillators

    TSI69.25
    Ultimate Osc59.8
    KST866.55

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$38,000$0$0$0$6,000$0
    Cost of Revenue$0$0$-45,000$0$0$0$10,000$0$0$0$6,000$0
    Gross Profit$0$0$45,000$0$0$0$-10,000$0$0$0$-6,000$0
    Operating Expenses$24.60M$22.29M$24.72M$18.38M$11.58M$15.97M$7.38M$8.63M$12.82M$7.78M$6.38M$10.22M
    R&D$22.34M$20.32M$21.89M$15.20M$8.62M$12.54M$5.26M$5.87M$5.74M$4.32M$3.57M$6.37M
    SG&A$2.27M$1.97M$2.83M$3.18M$2.96M$3.43M$2.12M$2.76M$7.08M$3.45M$2.81M$3.85M
    Operating Income$-24,603,000$-22,439,000$-24,571,000$-18,383,000$-11,579,000$-16,124,000$-7,351,000$-8,629,000$-12,818,000$-7,804,000$-6,381,000$-10,216,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-23,138,000$-21,763,000$-22,720,000$-18,383,000$-11,249,000$-15,656,000$-6,848,000$-8,392,000$-12,818,000$-7,420,000$-5,872,000$-9,955,000
    Income Tax Expense$193,000$373,000$0$0$0$0$0$0$0$0$0$0
    Net Income$-23,331,000$-22,136,000$-24,788,000$-17,682,000$-11,249,000$-15,656,000$-7,155,000$-8,392,000$-12,511,000$-7,420,000$-5,872,000$-9,955,000
    EBITDA$-24,159,000$-21,751,000$-24,543,000$-18,372,000$-11,234,000$-15,883,000$-7,497,000$-8,373,000$-12,813,000$-7,417,000$-6,990,000$-9,952,000
    EBIT$-23,138,000$-21,763,000$-24,571,000$-18,383,000$-11,249,000$-15,656,000$-7,351,000$-8,392,000$-12,818,000$-7,420,000$-6,996,000$-9,955,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FBRX

    News

    argenx Completes Acquisition of Forte Biosciences, Inc.

    argenx, a global immunology innovation company, has announced the successful completion of its acquisition of Forte Biosciences, Inc. This acquisition adds Forte's first-in-class anti-CD122 Antibody, FB102, to argenx's immunology pipeline. The news was released via GlobeNewswire on August 27, 2026.

    Barchart.com•8/27/26•
    Neutral

    Forte Biosciences earnings on deck as argenx deal looms

    Forte Biosciences is set to report its second-quarter earnings, likely its last as an independent company before its $2.2 billion acquisition by argenx closes. While the financial results are expected to show little drama due to the imminent acquisition, investors will be looking for updates on the acquisition timeline, progress in its Phase 2 celiac disease trial, and the company's cash position. The acquisition validates FB102, Forte's anti-CD122 antibody, which has shown promise in autoimmune conditions and received Fast Track designation for celiac disease.

    Investing.com•8/23/26•
    Bullish

    What Forte Biosciences (FBRX) bankers see in $77 cash bid

    Forte Biosciences (FBRX) has filed an amendment to its Schedule 14D-9 regarding the $77 per share cash tender offer by argenx BV. The amendment clarifies that Forte's executive officers have not yet finalized post-closing employment agreements and details the unaudited long-term financial projections used by the company's board and Guggenheim Securities, which include an estimated $43 million transaction fee for Guggenheim. The company also reported receiving nine demand letters alleging disclosure deficiencies, which it believes are without merit.

    Stock Titan•8/21/26•
    Somewhat-Bullish

    Forte Biosciences (FBRX) cash tender clears antitrust

    Forte Biosciences (FBRX) has received antitrust clearance for a cash tender offer by Avena Merger Sub Inc., a subsidiary of argenx. The offer seeks to acquire all outstanding Forte common shares at $77.00 per share. The HSR Act waiting period expired on August 18, 2026, satisfying a key condition, though other conditions for the offer remain.

    Stock Titan•8/19/26•
    Somewhat-Bullish

    Forte Biosciences (NASDAQ: FBRX) nears deal after U.S. antitrust wait expires

    Forte Biosciences (FBRX) is moving closer to its acquisition by argenx BV, with its wholly-owned subsidiary Avena Merger Sub Inc. offering $77.00 per share for all outstanding common shares. The required waiting period under the HSR Act has expired, satisfying a key antitrust-related closing condition for the merger. This update was disclosed in an amended Schedule 14D-9 filing by Forte Biosciences.

    Stock Titan•8/19/26•
    Bullish

    Frequently Asked Questions About FBRX

    Does FBRX pay dividends?
    Forte Biosciences Inc (FBRX) does not currently pay a regular dividend.
    What is FBRX's market cap?
    Forte Biosciences Inc (FBRX) has a market capitalization of $1.63B with a current stock price of $76.99.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In